Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 1/20 | 0.43 |
| ▸ | CCR3 | P51677 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.39 |
| ▸ | ACHE | P22303 | 2/20 | 0.39 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15014582 | 0.82 | ACHE (0.58) | JAK1HRH3ACHEKAT2BCHRNB2 | |
| SCHEMBL12767079 | 0.81 | KMT2A (0.41) | CCR3HRH3ACHE | |
| SCHEMBL8430036 | 0.81 | CHRNB2 (0.64) | CHRNB2CHRNA4 | |
| SCHEMBL12424398 | 0.81 | KAT2B (0.47) | ACHEKAT2BCHRNB2CHRNA4 | |
| SCHEMBL16015389 | 0.80 | PDE2A (0.43) | CHRM4 | |
| SCHEMBL19160313 | 0.79 | KDM4E (0.49) | CCR3ACHE | |
| SCHEMBL30635474 | 0.78 | LTA4H (0.43) | JAK1HRH3ACHEKAT2BCHRNB2 | |
| SCHEMBL12384405 | 0.78 | MGAT2 (0.42) | JAK1HRH3CHRM4ACHEKAT2B | |
| SCHEMBL803677 | 0.78 | KAT2B (0.40) | JAK1CCR3HRH3CHRM4ACHE | |
| SCHEMBL12424333 | 0.76 | CHRNB2 (0.66) | HRH3CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | CCNY, CCNA1, CCNA2 | JAK1 434/4885CCR3 324/4885HRH3 83/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.